58.92 -0.27 (-0.46%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 71.62 | 1-year : | 83.65 |
Resists | First : | 61.31 | Second : | 71.62 |
Pivot price | 59.42 ![]() |
|||
Supports | First : | 56.01 | Second : | 52.74 |
MAs | MA(5) : | 59.44 ![]() |
MA(20) : | 59.18 ![]() |
MA(100) : | 57.61 ![]() |
MA(250) : | 61.18 ![]() |
|
MACD | MACD : | 0.7 ![]() |
Signal : | 0.8 ![]() |
%K %D | K(14,3) : | 51.4 ![]() |
D(3) : | 57.4 ![]() |
RSI | RSI(14): 52.8 ![]() |
|||
52-week | High : | 70.8 | Low : | 52.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ANIP ] has closed above bottom band by 31.9%. Bollinger Bands are 52.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 59.48 - 59.97 | 59.97 - 60.29 |
Low: | 57.14 - 57.67 | 57.67 - 58.03 |
Close: | 58.21 - 59.05 | 59.05 - 59.61 |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Mon, 17 Feb 2025
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? - Yahoo Finance
Mon, 17 Feb 2025
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Wed, 12 Feb 2025
abrdn plc Makes New $13.16 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Tue, 11 Feb 2025
ANI Pharmaceuticals: More Than Just A Generics Company (NASDAQ:ANIP) - Seeking Alpha
Fri, 31 Jan 2025
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Fri, 31 Jan 2025
Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now? - Nasdaq
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
Shares Out | 21 (M) |
Shares Float | 16 (M) |
Held by Insiders | 10.5 (%) |
Held by Institutions | 101.1 (%) |
Shares Short | 2,290 (K) |
Shares Short P.Month | 2,350 (K) |
EPS | -0.47 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 20.73 |
Profit Margin | -1.3 % |
Operating Margin | -7.4 % |
Return on Assets (ttm) | 1.2 % |
Return on Equity (ttm) | -1.7 % |
Qtrly Rev. Growth | 12.5 % |
Gross Profit (p.s.) | 15.79 |
Sales Per Share | 26.42 |
EBITDA (p.s.) | 3.9 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 93 (M) |
Levered Free Cash Flow | 50 (M) |
PE Ratio | -125.37 |
PEG Ratio | 0 |
Price to Book value | 2.84 |
Price to Sales | 2.22 |
Price to Cash Flow | 13.33 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |